

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2015

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period to

Commission File No. 000-55364

HELIUS MEDICAL TECHNOLOGIES, INC.

(Exact name of Registrant as specified in its charter)

Wyoming
(State or other jurisdiction of
incorporation or organization)

36-4787690
(I.R.S. Employer
Identification Number)

Suite 400, 41 University Drive
Newton, Pennsylvania, 18940
(Address of principal executive office) (Zip Code)

(215) 809-2018
(Registrant's telephone number, including area code)

N/A
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:

Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer
(Do not check if a smaller reporting company)

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

<u>Class</u>	<u>Outstanding at November 13, 2015</u>
Class A Common Stock	66,637,653

INDEX

Part I.	Financial Information	
Item 1.	Interim Condensed Consolidated Financial Statements	
	Interim Condensed Consolidated Balance Sheets as of September 30, 2015 (Unaudited) and March 31, 2015	3
	Interim Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended September 30, 2015 and 2014 (Unaudited)	4
	Interim Condensed Consolidated Statement of Capital Deficit for the six months ended September 30, 2015 (Unaudited)	5
	Interim Condensed Consolidated Statements of Cash Flows for the six months ended September 30, 2015 and 2014 (Unaudited)	6
	Notes to Consolidated Financial Statements (unaudited)	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	20
Item 4.	Controls and Procedures	20
Part II.	Other Information	
Item 1.	Legal Proceedings	21
Item 1A.	Risk Factors	21
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21
Item 3.	Defaults Upon Senior Securities	21
Item 4.	Mine Safety Disclosures	22
Item 5.	Other Information	22
Item 6.	Exhibits	22

PART I — FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

HELIUS MEDICAL TECHNOLOGIES, INC.
INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2015
(Unaudited)
(Expressed in United States Dollars)

Helius Medical Technologies, Inc.
Interim Condensed Consolidated Balance Sheets
September 30, 2015 and March 31, 2015
(Unaudited)
(Expressed in United States Dollars)

	September 30, 2015	March 31, 2015
	\$	(audited) \$
ASSETS		
Current assets		
Cash and cash equivalents	192,256	418,893
Short-term investment	-	378,000
Receivables	115,672	8,833
Prepaid expenses	411,180	410,621
Total current assets	719,108	1,216,347
TOTAL ASSETS	719,108	1,216,347
LIABILITIES		
Current liabilities		
Accounts payable and accrued liabilities	1,140,904	1,197,804
Promissory note payable (Note 4)	200,000	-
Deferred expense reimbursement (Note 5)	120,847	-
Total current liabilities	1,461,751	1,197,804
Derivative liability (Note 6)	361,909	1,581,444
TOTAL LIABILITIES	1,823,660	2,779,248
CAPITAL DEFICIT		
Common stock (Unlimited Class A common shares authorized); (64,524,320 shares outstanding at September 30, 2015 and 63,104,788 shares outstanding at March 31, 2015) (Note 6)	19,109,428	16,358,093
Additional paid-in capital	1,819,735	1,490,790
Shares to be issued	-	39,545
Accumulated other comprehensive income	(1,498,533)	(971,640)
Accumulated deficit	(20,535,182)	(18,479,689)
TOTAL CAPITAL DEFICIT	(1,104,552)	(1,562,901)
TOTAL LIABILITIES & CAPITAL DEFICIT	719,108	1,216,347

"Philippe Deschamps " Director

"Savio Chiu " Director

(The accompanying notes are an integral part of these financial statements.)

Helius Medical Technologies Inc.
Interim Condensed Consolidated Statements of Comprehensive Income (Loss)
for the three and six months ended September 30, 2015 and 2014
(Unaudited)
(Expressed in United States Dollars)

	Three Months Ended September 30,		Six Months Ended September 30,	
	2015	2014	2015	2014
	\$	\$	\$	\$
Operating Expenses				
Advertising, marketing & investor relations	240,368	357,956	548,581	404,182
Audit & accounting	23,738	30,836	104,200	41,481
Consulting fees (Note 7)	20,199	36,013	163,021	236,862
Insurance	30,465	22,287	60,004	29,773
Legal fees	205,310	344,491	499,046	564,425
Meals & travel	31,803	77,611	127,670	107,052
Office & general	26,725	83,747	52,764	118,296
Research & development	243,262	1,062,927	1,629,938	1,716,186
Transfer agent & regulatory	16,373	43,713	48,952	58,973
Wages and salaries	223,349	295,017	662,414	465,998
Loss from operations	(1,061,592)	(2,354,598)	(3,896,590)	(3,743,228)
Other items				
Interest expense (Note 3)	-	-	-	(176,488)
Interest and other income	27,801	7,811	27,748	10,621
Change in fair value of derivative liability (Note 2)	1,484,174	(594,254)	1,305,796	(594,254)
Foreign exchange gain (loss)	588,978	(406,182)	507,553	(412,628)
	2,100,953	(992,625)	1,841,097	(1,172,749)
Net income (loss) for the period	1,039,361	(3,347,223)	(2,055,493)	(4,915,977)
Other comprehensive income				
Translation adjustments	(564,283)	206,786	(526,893)	312,845
Comprehensive income (loss) for the period	475,078	(3,140,437)	(2,582,386)	(4,603,132)
Net income (loss) per common share	0.02	(0.05)	(0.03)	(0.10)
Weighted average number of common shares outstanding	64,408,500	63,104,788	64,055,508	51,025,119

(The accompanying notes are an integral part of these financial statements.)

Helius Medical Technologies Inc.
Interim Condensed Consolidated Statements of Capital Deficit

for the six months ended September 30, 2015

(Unaudited)

(Expressed in United States Dollars)

	Common Stock	Amount \$	Additional Paid-In Capital \$	Shares to be Issued \$	Accumulated Deficit \$	Accumulated other comprehensive income (loss) \$	Capital (Deficit) \$
Balance – March 31, 2015	63,104,788	16,358,093	1,490,790	39,545	(18,479,689)	(971,640)	(1,562,901)
Exercise of finder's warrants	14,400	11,926	-	-	-	-	11,926
Issuance of common stock for private placement	849,273	1,825,937	-	-	-	-	1,825,937
Issuance of common stock for private placement	335,463	721,243	-	(39,545)	-	-	681,698
Issuance of common stock for private placement	125,756	270,375	-	-	-	-	270,375
Stock option exercise	94,640	42,500	-	-	-	-	42,500
Fair value of options exercised	-	20,454	(20,454)	-	-	-	-
Share issuance cost	-	(141,100)	-	-	-	-	(141,100)
Stock-based compensation on 2,570,000 options granted	-	-	188,426	-	-	-	188,426
Stock-based compensation on 400,000 options granted	-	-	198,151	-	-	-	198,151
Stock-based compensation on 100,000 options granted	-	-	21,644	-	-	-	21,644
Stock-based compensation on 100,000 options granted	-	-	21,021	-	-	-	21,021
Stock-based compensation on 50,000 options granted	-	-	6,418	-	-	-	6,418
Fair value of non- employee vested options reallocated to derivative liability	-	-	(86,261)	-	-	-	(86,261)
Net loss for the period	-	-	-	-	(2,055,493)	-	(2,055,493)
Translation	-	-	-	-	-	(526,893)	(526,893)

adjustments

Balance –							
September							
30, 2015	64,524,320	19,109,428	1,819,735	-	(20,535,182)	(1,498,533)	(1,104,552)

(The accompanying notes are an integral part of these financial statements.)

Helius Medical Technologies, Inc.
Interim Condensed Consolidated Statements of Cash Flows
for the six months ended September 30, 2015 and 2014
(Unaudited)
(Expressed in United States Dollars)

	September 30, 2015	September 30, 2014
	\$	\$
Cash flows from operating activities		
Net loss for the period	(2,055,493)	(4,915,977)
Items not involving cash:		
Change in fair value of derivative liability	(1,305,796)	594,254
Stock-based compensation	435,660	533,294
Accretion	-	176,488
Changes in non-cash working capital items:		
Receivables	(110,329)	(693)
Deferred expense reimbursement	120,847	-
Prepaid expenses	(1,736)	(84,459)
Accounts payable and accrued liabilities	(47,405)	937,740
Foreign exchange remeasurement	(429,494)	-
Net cash used in operating activities	(3,393,746)	(2,759,353)
Cash flows from investing activities		
Short term investment	378,000	-
Cash acquired on recapitalization	-	23,904
Proceeds from bridge loan	-	150,000
Net cash provided by investing activities	378,000	173,904
Cash flows from financing activities		
Proceeds from the issuance of shares	2,871,981	6,616,051
Share issue costs	(141,100)	-
Proceeds from issuance of promissory note	200,000	-
Proceeds from the issuance of convertible debt	-	633,195
Net cash provided by financing activities	2,930,881	7,249,246
Effect of foreign exchange rate changes on cash	(141,772)	320,261
Change in cash for the period	(84,865)	4,663,797
Cash, beginning of the period	418,893	15,968
Cash, end of the period	192,256	5,000,026
Supplemental cash flow information		
Interest paid in cash	-	11,144
Income taxes paid in cash	-	-

(The accompanying notes are an integral part of these financial statements.)

1. BASIS OF PRESENTATION

The accompanying unaudited condensed financial statements of Helius Medical Technologies Inc. (the “Company”) have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission (“SEC”) Regulation S-X. Accordingly, they should be read in conjunction with the audited consolidated financial statements and notes thereto for the fiscal year ended March 31, 2015 included in the Annual Report on Form 10-K filed with the SEC on June 29, 2015. The unaudited condensed consolidated interim financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the consolidated financial position of the Company at September 30, 2015, and the consolidated results of operations for the three and six months ended September 30, 2015, and consolidated statements of cash flows for the three months ended September 30, 2015. All intercompany accounts and transactions have been eliminated. It should be understood that accounting measures at interim dates inherently involve greater reliance on estimates than at year end. The results of operations for the three and six months ended September 30, 2015 are not necessarily indicative of the results to be expected for the full year or any future interim periods.

2. SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Liquidity

The Company has incurred a net loss of \$2,055,493 for the six months ended September 30, 2015 and, as of September 30, 2015, the Company has an accumulated deficit of \$20,535,182 (March 31, 2015 - \$18,479,689). Until the Company generates a level of revenue to support its cost structure, the Company expects to continue to incur substantial operating losses and net cash outflows. While the Company had cash and cash equivalents of \$192,256 as of September 30, 2015 (March 31, 2015 - \$418,893), management does not believe these resources will be sufficient to meet the Company’s operating and capital needs for the ensuing fiscal year.

The Company intends to fund ongoing activities by utilizing current cash and cash equivalents and by raising additional capital through equity or debt financings. There can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company. If the Company is unable to raise sufficient additional capital, the Company may be compelled to reduce the scope of its operations and planned capital expenditure or sell certain assets, including intellectual property assets. This material uncertainty gives rise to substantial doubt about the Company’s ability to continue as a going concern.

Fair Value of Financial Assets and Liabilities

The Company’s financial instruments consist primarily of cash and cash equivalents and accounts payable and accrued liabilities. The book values of these instruments approximate their fair values due to the immediate or short-term nature of those instruments.

ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value;

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and

Level 3 – Unobservable inputs that are supported by little or no market activity, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.

Cash and cash equivalents and short-term investment are measured using Level 1 inputs.

The Company had certain Level 3 liabilities required to be recorded at fair value on a recurring basis in accordance with US GAAP as at September 30, 2015. As at September 30, 2015, the Company’s Level 3 liabilities consisted of the grant of share Purchase options to non-employees. The resulting Level 3 liabilities have no active market and are required to be measured at their fair value each reporting period based on information that is unobservable.

A summary of the Company's Level 3 liabilities for the periods ended September 30, 2015 and March 31, 2015 are as follows:

	Six months ended September 30, 2015 \$	Year ended March 31, 2015 \$
Non-employee options		
Beginning fair value	1,581,444	-
Issuance	-	767,879
Reallocation of vested non-employee options	86,261	74,190
Change in fair value	(1,305,796)	739,375
Ending fair value of Level 3 liability	361,909	1,581,444

Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances (for example, when there is evidence of impairment). There were no assets or liabilities measured at fair value on a non-recurring basis during the periods ended September 30, 2015 and September 30, 2014.

Recent Accounting Pronouncements

In April 2015, the FASB issued Accounting Standards Update No. 2015-03 Interest – Imputation of Interest (Subtopic 835-30). This guidance is to simplify the presentation of debt issuance costs by recognizing a debt liability in the balance sheet as a direct deduction from that debt liability consistent with the presentation of a debt discount. The amendments in this Update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The Company is currently evaluating the impact of adoption of this new accounting pronouncement on its financial statements.

3. CONVERTIBLE DEBENTURE

On February 19, 2014, the Company entered into a securities purchase agreement where the Company agreed to sell and issue a note with annual simple interest at 8% (the "Debenture"). A total of \$1,000,100 in principal had been received.

On June 13, 2014, the Debenture matured on the closing of the Company's qualified financing. Upon completion of the qualified financing, the Debenture automatically converted into equity securities of the Company at a price per share equal to 85% of the price per share of the qualified financing. The conversion option of the Debenture was accounted for as a contingent beneficial conversion feature valued at \$176,488 which was recorded as interest expense in the Statement of Comprehensive Loss on settlement of the contingency.

4. PROMISSORY NOTE

On August 25, 2015, the Company received \$200,000 in exchange for the issuance of a promissory note. The promissory note was to be repaid six months from the date of issuance with interest at the rate of 6% per annum. In addition, the lender was entitled to receive 30,000 common shares of the Company on the date of the promissory note and 30,000 common every three months thereafter as long as the principal of the loan remained outstanding.

On October 28, 2015, the Company repaid the loan in its entirety and issued 30,000 common shares that were owed to the lender in accordance with the terms of the promissory note.

5. DEFERRED EXPENSE REIMBURSEMENT

During the six months ended September 31, 2015, pursuant to the sole-source cost sharing contract executed with the U.S. Army Medical Research and Materiel Command, the Company received a total of \$1,037,089 in respect of expenses reimbursed for registrational trial ("the trial") investigating the safety and effectiveness of the portable neuromodulation stimulator for mild to moderate traumatic brain injury. Upon receipt, the Company recorded these funds as a deferred expense reimbursement to be applied against charges incurred by the Company as the trial progresses. As of September 30, 2015, the Company had incurred costs of \$916,972 on the trial with the remaining \$120,847 applied subsequent to September 30, 2015.

6. COMMON STOCK

Authorized:

Unlimited Class A common shares without par value.

Each Class A common share is entitled to have the right to vote at any shareholder meeting on the basis of one vote per share. Each Class A share held entitles the holder to receive dividends as declared by the directors. In the event of the liquidation, dissolution or winding-up of the Company other distribution of assets of the Company among its shareholders for the purposes of winding-up its affairs or upon a reduction of capital the holders of the Class A common shares shall, share equally, share for share, in the remaining assets and property of the Company.

Class B common shares and Class A preferred shares were deleted from the list of classes of shares the Company is authorized to issue by way of amendment to the Company's articles effective June 12, 2014.

The Company is subject to a stockholders agreement, which places certain restrictions on the Company's stock and its stockholders. These restrictions include approvals prior to sale or transfer of stock, a right of first refusal to purchase stock held by the Company and a secondary right of refusal to stockholders, right of co-sale whereby certain stockholders may be enabled to participate in a sale of other stockholders to obtain the same price, term and conditions on a pro-rata basis, rights of first offer of new security issuances to current stockholders on a pro-rata basis and certain other restrictions.

On April 30, 2015 the Company closed a non-brokered private placement (the "First Financing") raising gross proceeds of \$1,825,937 by the issuance of 849,273 units (each a "First Financing Unit") at a price of \$2.15 per First Financing Unit. Each First Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a "First Financing Warrant"). Each whole First Financing Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of \$3.00 per share for a period of thirty-six (36) months from the closing date of the Financing. The Company paid a cash finder's fee of \$84,074 in connection with this First Financing, as well as 27,396 finder's warrants (the "First Financing Finder's Warrants"). Each First Financing Finder's Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of \$3.00 per share for a period of thirty-six (36) months from the closing date of the First Financing.

On June 26, 2015 the Company closed a non-brokered private placement (the "Second Financing") raising gross proceeds of \$721,243 by the issuance of 335,463 units (each a "Second Financing Unit") at a price of \$2.15 per Second Financing Unit. Each Second Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a "Second Financing Warrant"). Each whole Second Financing Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of \$3.00 per share for a period of thirty-six (36) months from the closing date of the Second Financing. The Company paid a cash finder's fee of \$40,803 in connection with this Second Financing, as well as 18,978 finder's warrants (the "Second Financing Finder's Warrants"). Each Second Financing Finder's Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of \$2.15 per share for a period of sixty (60) months from the closing date of the Second Financing.

On July 17, 2015 the Company closed a non-brokered private placement (the "Third Financing") raising gross proceeds of \$270,375 by the issuance of 125,756 units (each a "Third Financing Unit") at a price of \$2.15 per Third Financing Unit. Each Third Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a "Third Financing Warrant"). Each whole Third Financing Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of \$3.00 per share for a period of thirty-six (36) months from the closing date of the Third Financing. The Company paid a cash finder's fee of \$16,223 in connection with this Third Financing, as well as 7,545 finder's warrants (the "Third Financing Finder's Warrants"). Each Third Financing Finder's Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of \$2.15 per share for a period of sixty (60) months from the closing date of the Third Financing.

7. SHARE BASED PAYMENTS

(a) Stock options

The Company has a stock option plan whereby the Company is authorized to grant up to 12,108,016 options. Vesting and the term of an option is determined at the discretion of the Board of Directors of the Company.

The continuity of stock options for the periods as at September 30 and March 31, 2015, are as follows:

	Number	Weighted Average Exercise Price (CAD)	Aggregate Intrinsic Value (CAD)
Balance outstanding at March 31, 2015	4,920,000	\$ 1.14	\$ 10,120,000
Exercised	(94,640)	\$ 0.60	-
Granted	50,000	0.98	-
Balance outstanding at September 30, 2015	4,875,360	\$ 1.15	\$ -
Balance exercisable at September 30, 2015	3,272,862	\$ 1.15	\$ -

The options outstanding and exercisable at September 30, 2015 are as follows:

Number of options	Expiry date	Options outstanding remaining contractual life (years)	Exercise Price (CAD)	Grant date fair value (CAD)	Number of options exercisable
3,520,000	June 18, 2019	3.72	\$ 0.60	\$ 0.23	2,346,667
155,360	June 20, 2019	3.72	\$ 0.60	\$ 0.23	92,860
100,000	July 14, 2017	1.79	\$ 2.52	\$ 1.06	100,000
450,000	December 8, 2019	4.19	\$ 2.92	\$ 1.65	450,000
100,000	December 8, 2019	4.19	\$ 2.92	\$ 1.49	33,334
400,000	December 8, 2019	4.19	\$ 2.96	\$ 1.56	200,000
100,000	March 16, 2020	4.46	\$ 3.20	\$ 1.61	33,334
50,000	August 15, 2015	4.88	\$ 0.98	\$ 0.45	16,667
4,875,360					3,272,862

The fair value of stock options vested during the periods ended September 30, 2015 and September 30, 2014 were estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

	September 30, 2015	September 30, 2014
Stock price	\$ 0.872	\$ 0.55
Exercise Price	\$ 1.105	\$ 0.65
Expected life	4.1 years	4.1 years
Expected volatility	67.85%	115.73%
Risk – free interest rate	1.05%	1.46%
Dividend rate	0.00%	0.00%

The Company has adopted the simplified method prescribed by the SEC in SAB Topic 14 in respect of estimating the expected term of its stock options as its limited share purchase option history does not provide a reasonable basis to estimate the expected terms. Expected volatility was determined by reference to the average volatility rates of other companies in the same industry due to the Company's limited trading history.

Non-Employee Stock Options

In accordance with the guidance of ASC 815-40-15, stock options awarded to non-employees that are performing services for Neuro are required to be accounted for as derivative liabilities once the services have been performed and the options have vested because they are considered not to be indexed to the Company's stock due to their exercise price being denominated in a currency other than Neuro's functional currency. Stock options awarded to non-employees that are not vested are accounted for as equity awards until the terms associated with their vesting requirements have been met.

The non-employee stock options are accounted for at their respective fair values and are summarized as follows for the periods ended September 30, 2015 and March 31, 2015:

	Six months ended September 30, 2015 \$	Year ended March 31, 2015 \$
Fair value of non-employee options, beginning of the period	1,581,444	-
Issuance	-	767,879
Reallocation of vested non-employee options	86,261	74,190
Change in fair value of non-employee stock options during the period	(1,305,796)	739,375
Fair value of non-employee options, end of the period	361,909	1,581,444

The non-employee options are required to be re-valued with the change in fair value of the liability recorded as a gain or loss on the change of fair value of derivative liability and included in other items in the Company's Consolidated Statements of Loss at the end of each reporting period. The fair value of the options will continue to be classified as a liability until such time as they are exercised, expire or there is an amendment to the respective agreements that renders these financial instruments to be no longer classified as a liability.

Share-based payments are classified in the Company's Statement of Loss as follows for the period ended September 30, 2015 and 2014:

	September 30, 2015 \$	September 30, 2014 \$
Consulting fees	73,126	70,654
Research and development	-	50,303
Wages and salaries	362,534	473,297
	435,660	594,254

(b) **Share Purchase Warrants**

The Company closed its First Financing at \$2.15 per First Financing Unit of 849,273 First Financing Units raising \$1,825,937 on April 30, 2015. Each First Financing Unit consists of one common stock of the Company and one half of a First Financing Warrant of the Company where one full First Financing Warrant is exercisable for 3 years at \$3.00 into one common share. The Company also issued 27,396 First Financing Finder's Warrants. Each First Financing Finder's Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of \$3.00 per share for a period of thirty-six (36) months from the closing date of the First Financing.

The Company closed its Second Financing at \$2.15 per Second Financing Unit of 335,463 Second Financing Units raising \$721,243 on June 26, 2015. Each Second Financing Units consists of one common stock of the Company and one half of a Second Financing Warrant of the Company where one full Second Financing Warrant is exercisable for 3 years at \$3.00 into one common share. The Company also issued 18,978 Second Financing Finder's Warrants. Each Second Financing Finder's Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of \$2.15 per share for a period of sixty (60) months from the closing date of the Second Financing.

The Company closed its Third Financing at \$2.15 per Third Financing Unit of 125,756 Third Financing Units raising \$270,375 on July 17, 2015. Each Third Financing Units consists of one common stock of the Company and one half of a Third Financing Warrant of the Company where one full Third Financing Warrant is exercisable for 3 years at \$3.00 into one common share. The Company also issued 7,545 Third Financing Finder's Warrants. Each Third Financing Finder's Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of \$2.15 per share for a period of sixty (60) months from the closing date of the Third Financing.

The continuity of warrants for the six months ended September 30, 2015 is as follows:

	Number of warrants		Weighted Average Exercise Price	
	CAD	US	CAD \$	US \$
Balance, March 31, 2015	8,444,400	-	\$ 1.00	-
Granted	-	709,164	\$ -	2.97
Exercised	(14,400)	-	\$ 1.00	-
Balance, September 30, 2015	8,430,000	709,164	\$ 1.00	2.97

The warrants outstanding and exercisable at September 30, 2015 are as follows:

Number of warrants outstanding	Exercise Price	Expiry Date
8,430,000	CAD \$1.00	May 30, 2016
452,032	US \$ 3.00	April 30, 2018
167,731	US \$ 3.00	June 26, 2018
18,978	US \$ 2.15	June 26, 2020
62,878	US \$ 3.00	July 17, 2018
7,545	US \$ 2.15	July 17, 2020

8. COMMITMENTS AND CONTINGENCIES

- (a) The Company entered into a license agreement with Advanced NeuroRehabilitation, LLC (“ANR”) for an exclusive right on ANR’s patent pending technology, claims and knowhow. In addition to the issuance of 16,035,026 shares, the Company agreed to pay a 4% royalty on net revenue on the sales of devices covered by the patent-pending technology and services related to the therapy or use of devices covered by the patent-pending technology.
- (b) On March 7, 2014, the Company entered into a commercial development-to-supply program with Ximedica where Ximedica will design, develop and produce PoNS product solution suitable for clinical trial and commercial sale. Under the program, the Company is responsible for ensuring the device is in compliance with relevant laws and regulations. The agreed budget for phase 1B of development is \$499,000; phase 2 is \$1,065,000; Phase 3 and 4 is \$1,389,000 and 2nd software development cycle is \$586,000, of which \$4,147,423 was expensed as research and development since inception to September 30, 2015. Invoices are to be issued monthly for work in progress. The Company can cancel the project at any time with a written notice at least 30 days prior to the intended date of cancellation. As of September 30, 2015, the Company recorded a prepaid expense of \$300,000 to Ximedica which will be applied at the end of the project. During the period ended September 30, 2015, the Company incurred charges of \$797,425 (September 30, 2014 - \$1,544,291) pursuant to this agreement.
- (c) On January 27, 2015 we received a demand letter containing allegations that we had entered into a consulting arrangement with the complainants and breached certain of its terms, and used certain intellectual property in the form of business and marketing plans allegedly prepared by the complainants, and seeking damages. On May 7, 2015, Mr. Rainer Maas and Dr. Jochen Scheld filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania seeking monetary damages. Document discovery ends on October 23, 2015, a settlement conference with the magistrate judge is scheduled for December 2, 2015, discovery ends on February 26, 2016, and trial is scheduled for April 8, 2016. Management estimates that the contingent liability of such claim to be immaterial.

9. RELATED PARTY TRANSACTIONS

For the period ended September 30, 2015, the Company was a party to the following related party transactions:

During the period ended September 30, 2015, the Company paid \$49,560 (September 30, 2014 - \$6,050) in consulting fees to directors of the Company.

During the period ended September 30, 2015, the Company paid \$59,175 (September 30, 2014 - \$34,418) to a company acting as the Company’s corporate advisor and employing its former Chief Financial Officer.

10. SUBSEQUENT EVENTS

- a) On October 13, 2015, the Company announced that it entered into strategic agreements with A&B Company Limited (“A&B”) for the development and commercialization of the Portable Neuromodulation Stimulator (“PoNS™”) Therapy in China, Hong Kong, Macao, Taiwan and Singapore (the “Territories”). The agreement, a sale and licensing transaction, transfers ownership of certain patents, patent applications, and product support material for the PoNS™ device in the Territories to A&B. A&B assumes all development, patent (both application and defense), future manufacturing, clinical trial, and regulatory approval costs for the Territories. Heliuss and A&B will share and transfer ownership of any intellectual property or support material (developed by either party) for their respective geographies.

As consideration for the transfer of the intellectual property, the Company will receive:

- a per unit handling fee relating to the amount paid by A&B for any PoNS™ devices and relevant components purchased by A&B from NHC, an affiliate of Heliuss, or its designated manufacturer for the licensed territories, if any.
- Heliuss would also be entitled to a one-time milestone payment if a certain sales milestone within the Territories is reached.

A&B will provide a US\$7.0 million funding commitment to Heliuss. The first US\$2.0 million of this commitment has been drawn down and Heliuss will issue a convertible promissory note. As agreed, Heliuss will repay the US \$2.0 million note through the issuance of approximately 2,083,333 shares of Heliuss’s common stock at a price of US \$0.96 per share and approximately 1,041,667 3-year warrants with an exercise price of US \$1.44. Heliuss issued the shares of common stock and the warrants to A&B on November 10, 2015. The Company can elect to draw down the remaining US \$5.0 million in the commitment within six months through issuing additional shares and warrants at a price based on the volume weighted average closing price of the Company’s shares of common stock. The funding commitment contains certain customary events of default, and may be cancelled or withdrawn if there is a material obstacle with regards to the PoNS™ obtaining eventual regulatory approval in the United States. Heliuss intends to, but is not obliged to, draw against the remainder of the funding commitment within the next six months to fund the continued development of the PoNS™ device.

- b) On October 21, 2015, the Company issued 750,000 options to an officer of the Company. The options are exercisable at CAD \$0.87 for 5 years from the grant date. One-quarter of these options vested immediately, and the remaining options vest at a rate of 25% every year.
- c) On October 28, 2015, the Company issued 950,000 options to consultants and officers of the Company. The options are exercisable at CAD \$0.84 for 5 years from the grant date. 614,000 options vest immediately, and the remaining 336,000 options vest at a rate of 14% every 6 months.

Item 2. Management's Discussion And Analysis Of Financial Condition And Results Of Operations

In this quarterly report on Form 10-Q, unless otherwise specified, references to “we”, “us” or “our” mean Helius Medical Technologies, Inc. and its wholly-owned subsidiaries, NeuroHabilitation Corporation, or NHC, and Helius Medical Technologies (Canada), Inc., unless the context otherwise requires. All financial information is stated in U.S. dollars unless otherwise specified. Our financial statements are prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP.

FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q contains forward-looking statements that involve risks and uncertainties, including statements regarding our market, strategy, competition, capital needs, business plans and expectations. Such forward-looking statements involve risks and uncertainties regarding the success of our business plan, availability of funds, government regulations, operating costs, our ability to achieve significant revenues and other factors. Forward-looking statements are made, without limitation, in relation to operating plans, availability of funds and operating costs. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict”, “potential” or “continue”, the negative of such terms or other comparable terminology. Actual events or results may differ materially. In evaluating these statements, you should consider various factors, including the risks outlined in this annual report. These factors may cause our actual results to differ materially from any forward-looking statements. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith, based on information available to us as of the date hereof, and reflect our current judgment regarding our business plans, our actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested herein. We do not intend to update any of the forward-looking statements to conform these statements to actual results, except as required by applicable law, including the securities laws of the United States.

INDUSTRY AND MARKET DATA

Within this quarterly report on Form 10-Q, we reference information, statistics and estimates regarding the medical devices and healthcare industries. We have obtained this information from various independent third-party sources, including independent industry publications, reports by market research firms and other independent sources. This information involves a number of assumptions and limitations, and we have not independently verified the accuracy or completeness of this information. Some data and other information are also based on the good faith estimates of management, which are derived from our review of internal surveys and independent sources. We believe that these external sources and estimates are reliable but have not independently verified them. The industries in which we operate are subject to a high degree of uncertainty and risk due to a variety of factors, including those described in “Item 1A. Risk Factors” in our annual report on Form 10-K for the fiscal year ended March 31, 2015. These and other factors could cause results to differ materially from those expressed in these publications and reports.

Overview

We are a medical technology company focused on neurological wellness. We seek to develop, license or acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself.

Our mission is to develop, license and acquire non-invasive treatments designed to help patients affected by neurological symptoms caused by disease or trauma. Applying the principles of neuroplasticity, our patented PoNS™ device induces Cranial Nerve Non Invasive Neuromodulation that utilizes the brain’s innate ability to achieve neuroplastic change to aid persons with neurological, cognitive, sensory, and motor disorders when combined with the rehabilitation process.

The following discussion and analysis of our results of operations, financial condition and plan of operations should be read in conjunction with our audited financial statements for the year ended March 31, 2015. The discussion below contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including, but not limited to, those set forth under “Item 1. Business – Business Uncertainties and Going Concern Risk” and elsewhere in our annual report on Form 10-K for the fiscal year ended March 31, 2015.

Results of Operations

Three and Six Months Ended September 30, 2015 Compared to the Three and Six Months Ended September 30, 2014

Revenues

During the three and six months ended September 30, 2015 and September 30, 2014, we did not generate any revenues from the commercial sales of products or services.

Operating Expenses

Operating expenses incurred during the three months ended September 30, 2015 were \$1,061,592 (September 30, 2014 - \$2,354,598) and \$3,896,590 during the six months ended September 30, 2015 (September 30, 2014 - \$3,743,228). Significant changes and expenditures are outlined as follows:

- Advertising, marketing, and IR expenses were \$240,368 for the three months ended September 30, 2015 (September 30, 2014 - \$357,956) and \$548,581 for the six months ended September 30, 2015 (September 30, 2014 - \$404,182). The increase of \$144,399 between the six-month periods relates to an increase in advertising and promotion expenses and investor relation consulting fees. We have engaged both investor relations and public relations professionals in Canada and the US to help develop corporate material as well as arranging and participating in conferences and road shows to increase the public's awareness of our activities and the PoNS™ device.
- Audit and accounting fees were \$23,738 for the three months ended September 30, 2015 (September 30, 2014 - \$30,836) and \$104,200 for the six months ended September 30, 2015 (September 30, 2014 - \$41,481). Despite a decrease between the three-month periods of \$7,098, audit and accounting fees increased by \$62,719 between the six-month periods, mainly due to the requirement to review and audit the Company's financial statements since it became a reporting issuer in the United States.
- Consulting fees were \$20,199 for the three months ended September 30, 2015 (September 30, 2014 - \$36,013) and \$163,021 for the six months ended September 30, 2015 (September 30, 2014 - \$236,862). The decrease over the three and six month periods was mainly due to the initial expense recorded during the three and six month periods ended September 30, 2014, associated with the granting of options to consultants for providing services in design and manufacturing and our strategic growth plan.
- Insurance expenses were \$30,465 for the three months ended September 30, 2015 (September 30, 2014 - \$22,287) and \$60,004 for the six months ended September 30, 2015 (September 30, 2014 - \$29,773). The increase over the three and six month periods in insurance expenses was mainly due to the need for general liability, directors' and officers', and product insurance as the Company continues its research and development plans.
- Legal fees were \$205,310 for the three months ended September 30, 2015 (September 30, 2014 - \$344,491) and \$499,046 for the six months ended September 30, 2015 (September 30, 2014 - \$564,425). The decrease in legal fees was primarily due to the fact that we limited significant legal expenditures over the three and six month periods. Our legal activity to ensure current and quality regulatory filings increased significantly since becoming a public company in Canada, but we now have established practices that have helped us control our fees. The engagement of various specialized legal counsels for the development of our intellectual properties and the commercialization of the PoNS™ device is still being carried out to secure our intellectual property, including the issuance of three patents.

- Meals and travel expenses were \$31,803 for the three months ended September 30, 2015 (September 30, 2014 - \$77,611) and \$127,670 for the six months ended September 30, 2015 (September 30, 2014 - \$107,052). The increase of \$20,618 between the six-month periods was primarily due to expenses incurred while traveling to and from various investor and medical conferences as well as required travel for personnel to coordinate fundraising efforts and our clinical trials.
- Office expenses were \$26,725 for the three months ended September 30, 2015 (September 30, 2014 - \$83,747) and \$52,764 for the six months ended September 30, 2015 (September 30, 2014 - \$118,296). The significant decrease in office expenses for the three and six month periods was mainly due to the fact that we have established our operations and acquired all necessary office equipment in order to carry out our operations. Office expenses include general and administrative expenses as well as computer and internet expenses, telephone expenses, professional fees, and rent expenses.
- Research and development expenses were \$243,262 for the three months ended September 30, 2015 (September 30, 2014 - \$1,062,927) and \$1,629,938 for the six months ended September 30, 2015 (September 30, 2014 - \$1,716,186). The general decrease in R&D expenditures was primarily due to a slight deceleration in the continuous efforts on research and development activities of the PoNS™ device, especially activities relating to preparation of clinical trials which mostly includes our commercial development-to-supply program with Ximedica, LLC (“Ximedica”), a contract manufacturer, and the NeuroFeedback's 12- month pilot clinical trial.
- During the six months ended September 31, 2015, pursuant to the sole-source cost sharing contract executed with the U.S. Army Medical Research and Materiel Command (the “USAMRMC”) the Company received reimbursement for a total of \$1,037,089 in research and development expenses for the registrational trial investigating the safety and effectiveness of the portable neuromodulation stimulator. Upon receipt, the Company recorded these funds as a deferred expense reimbursement to be applied against charges incurred by the Company as the trial progresses. As of September 30, 2015, the Company had incurred costs of \$916,972 on the trial with the remaining \$120,847 applied subsequent to September 30, 2015.
- Transfer agent and regulatory fees were \$16,373 for the three months ended September 30, 2015 (September 30, 2014 - \$43,713) and \$48,952 for the six months ended September 30, 2015 (September 30, 2014 - \$58,973). The decrease in transfer agent and regulatory fees between the three and six month periods stems from the reduced regulatory filing requirements compared to previous fiscal period, especially considering a large majority of the fees from fiscal 2014 were associated with listing on the Canadian Securities Exchange and initial US regulatory filings.
- Wages and salaries expenses were \$223,349 for the three months ended September 30, 2015 (September 30, 2014 - \$295,017) and \$662,414 for the six months ended September 30, 2015 (September 30, 2014 - \$465,998). The amounts accounted for as wages and salaries decreased by \$71,668 between the three-month periods due to partial funding received from the USAMRMC of \$117,462 that were directly attributable to wages.

Non-Operating Items

We recorded gains of \$2,100,953 in respect of non-operating items during the three months ended September 30, 2015 (September 30, 2014 – losses of \$992,625) and gains of \$1,841,097 for the six months ended September 30, 2015 (September 30, 2014 – losses of \$1,172,749). Significant changes are outlined as follows:

- Interest expense of \$nil for the six months ended September 30, 2015 (September 30, 2014 – \$176,488). These changes relate to the accretion of convertible debenture discount which was converted and settled in fiscal 2015.

- Interest and other income for the three months ended September 30, 2015 was \$27,801 (September 30, 2014 - \$7,811) and \$27,748 for the six months ended September 30, 2015 (September 30, 2014 - \$10,621). Income from interest related to our cash held in interest bearing accounts. Income increased slightly due to the Company's sale of some prototype devices to testing facilities in Canada, Australia, Russia, and the US.
- Change in fair value of derivative liability for the three months ended September 30, 2015 was \$1,484,174 (September 30, 2014 - \$(594,254)) and \$1,305,796 for the six months ended September 30, 2015 (September 30, 2014 - \$(594,254)). The change in fair value of derivative liability is based on the change of the remaining term of our options granted to non-employees providing services for NHC and the change in our stock price. The derivative liabilities do not represent cash liabilities.
- Foreign exchange gains for the three months ended September 30, 2015 were \$588,978 (September 30, 2014 – losses of \$406,182) and gains of \$507,553 for the six months ended September 30, 2015 (September 30, 2014 – losses of \$412,628). The gains for the current three and six month periods stem from our predominantly US dollar holdings, while the loss for the comparative three and six month periods stem from the translation of the balance of the Canadian dollar intercompany accounts to the reporting currency.

Net income (loss)

The net income was \$1,039,361 for the three months ended September 30, 2015 (September 30, 2014 – net loss of \$(3,347,223)) and a net loss of \$2,055,493 for the six months ended September 30, 2015 (September 30, 2014 – net loss of \$(4,915,977)). The decrease in net losses between the six-month periods of \$2,860,484 resulted primarily from a decrease in most operating expenses, especially accreted interest expense, consulting fees, legal fees, office and general expenses, and research and development, as well as material gains in the change in fair value of the derivative liability and foreign exchange.

Liquidity and Capital Resources

Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, does not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation.

The following table sets out our cash and working capital as of September 30, 2015 and March 31, 2015:

	September 30, 2015	March 31, 2015
Cash and cash equivalents	\$ 192,256	\$ 418,893
Working capital (deficit)	\$ (742,643)	\$ 18,543

As of September 30, 2015, our current assets were \$719,108 (March 31, 2015 - \$1,216,347), which decreased mostly due to the Company's operational expenditures. Current liabilities of \$1,461,751 (March 31, 2015 - \$1,197,804) increased due to an increase in our operations since the closing of a private placement and our acquisition of NHC. Working capital was (\$742,645) (March 31, 2015 – \$18,543). Our current assets as of September 30, 2015 consisted of cash and cash equivalents of \$192,256 (March 31, 2015 - \$418,893), which decreased mostly due to increased operations and cash outflows, short-term investment of \$nil (March 31, 2015 - \$378,000), which decreased as a result of cashing and closing certain term deposits with our banking institution, receivables of \$115,672 (March 31, 2015 - \$8,833), which increased due to the larger amount of refundable Canadian commodity tax based on the Company's increase in Canadian operations, and prepaid expenses of \$411,180 (March 31, 2015 - \$410,621), which include a prepayment to Ximedica, software payments, and insurance payments. Our current liabilities as of September 30, 2015 consisted of accounts payable and accrued liabilities of \$1,140,904 (March 31, 2015 - \$1,197,804), which increased due to our increased operations, a deferred expense reimbursement of \$120,847 (March 31, 2015 - \$nil), which stems from the USAMRMC's reimbursement of certain research and development expenditures that have not yet been incurred, and a short-term loan of \$200,000 (March 31, 2015 - \$nil).

As a result of our increased activity, the accumulated deficit increased from \$18,479,689 as at March 31, 2015 to \$20,535,182 as of September 30, 2015.

We currently have limited working capital and liquid assets. Our cash and cash equivalents as of September 30, 2015 were \$192,256. To date we have not generated any revenue from the commercial sales of products or services. There are a number of conditions that we must satisfy before we will be able to generate revenue, including but not limited to successful completion of the design of the PoNS™ device, FDA clearance of the PoNS™ device for treating balance disorder associated with mild to moderate TBI and MS, manufacturing of a commercially-viable version of the PoNS™ device and demonstration of effectiveness sufficient to generate commercial orders by customers for our product. While we are currently seeking additional funding, we do not currently have sufficient resources to accomplish any of these conditions necessary for us to generate revenue. We will therefore require substantial additional funds in order to continue to conduct the research and development and regulatory clearance and approval activities necessary to bring our product to market, to establish effective marketing and sales capabilities and to develop other product candidates.

We will have to continue to rely on equity and debt financing. There can be no assurance that financing, whether debt or equity, will always be available to us in the amount required at any particular time or for any particular period or, if available, that it can be obtained on terms satisfactory to us. Without additional financing, we do not believe our resources will be sufficient to meet our operating and capital needs through the third quarter of 2016.

Statement of Cash Flows

Six Months ended September 30, 2015 compared to the Six Months ended September 30, 2014

During the six months ended September 30, 2015, our net cash decreased by \$84,865 (September 30, 2014 – increase of \$4,984,058), which included net cash used in operating activities of \$3,393,746 (September 30, 2014 - \$2,759,353) stemming from our increase in operations, net cash provided by investing activities of \$378,000 (September 30, 2014 - \$173,904) stemming from the receipt of a short-term investment and net cash provided by financing activities of \$2,930,881 (September 30, 2014 - \$7,249,246) stemming mainly from the closing of multiple private placements.

Cash Used in Operating Activities

Operating activities in the six months ended September 30, 2015 used cash of \$3,393,746 (September 30, 2014 - \$2,759,353). This was made up of a net loss of \$2,055,493 (September 30, 2014 - \$4,915,977) less adjustments for non-cash items such as accretion of beneficial conversion feature of \$nil (September 30, 2014 – \$176,488), change in fair value of derivative liability of \$1,305,796 (September 30, 2014 – \$(594,254)), stock based compensation of \$435,660 (September 30, 2014 - \$533,294), receivables of \$(110,329) (September 30, 2014 - \$(693)), accounts payable of \$(47,405) (September 30, 2014 – \$937,740), prepaid expenses of \$120,847 (September 30, 2014 – \$84,459) and foreign exchange on re-measurement of \$429,494 (September 30, 2014 - \$nil). Receivables increased due to the higher amount of refundable Canadian commodity tax. Prepaid expenses increased due to our increase in operations, while payables decreased due to the fact that we paid off some material amounts owing throughout the six month period.

Cash Provided by Investing Activities

During the six months ended September 30, 2015, cash provided by investing activities totaled \$378,000 (September 30, 2014 - \$173,904). This was made up of receipt of a short-term investment. The previous period's activities included cash acquired from the recapitalization of \$23,904 and proceeds from a bridge financing of \$150,000.

Cash Provided by Financing Activities

During the six months ended September 30, 2015, financing activities provided cash of \$2,930,881 (September 30, 2014 - \$7,249,246). Financing activities during the six month period ended September 30, 2015, consisted of: issuance of share capital of \$2,871,981 (September 30, 2014 - \$6,616,051) stemming from multiple private placements, share issue costs of \$141,100 (September 30, 2014 - \$nil), proceeds from a promissory note of \$200,000 (September 30, 2014 - \$nil), and proceeds from the debenture of \$nil (September 30, 2014 - \$633,195). On August 25, 2015, the Company received \$200,000 in exchange for the issuance of the promissory note. The promissory note was to be repaid six months from the date of issuance with interest at the rate of 6% per annum. In addition, the lender was entitled to receive 30,000 common shares of the Company on the date of the promissory note and 30,000 common every three months thereafter as long as the principal of the loan remained outstanding.

Off Balance Sheet Arrangements

To the best of management's knowledge, there are no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our results of operations or financial condition.

Recently Issued Accounting Pronouncements

In April 2015, the FASB issued Accounting Standards Update No. 2015-03 Interest – Imputation of Interest (Subtopic 835-30). This guidance is to simplify the presentation of debt issuance costs by recognizing debt issuance costs in the balance sheet as a direct deduction from that debt liability consistent with the presentation of a debt discount. The amendments in this Update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The Company is currently evaluating the impact of adoption of this new accounting pronouncement on its financial statements.

Subsequent Events

- a) On October 13, 2015, the Company announced that it entered into strategic agreements with A&B Company Limited (“A&B”) for the development and commercialization of the Portable Neuromodulation Stimulator (“PoNSTM”) Therapy in China, Hong Kong, Macao, Taiwan and Singapore (the “Territories”). The agreement, a sale and licensing transaction, transfers ownership of certain patents, patent applications, and product support material for the PoNSTM device in the Territories to A&B. A&B assumes all development, patent (both application and defense), future manufacturing, clinical trial, and regulatory approval costs for the Territories. Helius and A&B will share and transfer ownership of any intellectual property or support material (developed by either party) for their respective geographies.

As consideration for the transfer of the intellectual property, the Company will receive:

- a per unit handling fee relating to the amount paid by A&B for any PoNSTM devices and relevant components purchased by A&B from NHC, an affiliate of Helius, or its designated manufacturer for the licensed territories, if any.
- Helius would also be entitled to a one-time milestone payment if a certain sales milestone within the Territories is reached.

A&B will provide a US\$7.0 million funding commitment to Helius. The first US\$2.0 million of this commitment will be immediately drawn down and Helius will issue a convertible promissory note to A&B. As agreed, Helius will repay the US \$2.0 million note through the issuance of approximately 2,083,333 million shares of Helius common stock at a price of US \$0.96 per share and approximately 1,041,667 3-year warrants with an exercise price of US \$1.44. The Company can elect to draw down the remaining US \$5.0 million in the funding commitment for a period of six months by issuing additional shares and warrants at a price based on the volume weighted average closing price of the Company's shares of common stock. The funding commitment contains certain customary events of default, and may also be cancelled or withdrawn if there is a material obstacle with regards to the PoNSTM device obtaining eventual regulatory approval in the United States. Helius intends to, but is not obliged to, draw against the remainder of the credit facility within the next six months to fund the continued development of the PoNSTM device.

- b) On October 21, 2015, the Company issued 750,000 options to an officer of the Company. The options are exercisable at CAD \$0.87 for 5 years from the grant date. One-quarter of these options vests immediately, and the remaining options vest at a rate of 25% every year.
- c) On October 28, 2015, the Company issued 950,000 options to consultants and officers of the Company. The options are exercisable at CAD \$0.84 for 5 years from the grant date. 614,000 options vest immediately, and the remaining 336,000 options vest at a rate of 14% every 6 months.
- d) On October 28, 2015, the Company repaid the promissory note in its entirety and issued 30,000 common shares that were owed to the lender in accordance with the terms of the promissory note.
- e) On November 2, 2015, the Company announced positive clinical trial results for a Multiple Sclerosis pilot study evaluating its PoNS™ device. The independent trial took place at the Montreal Neurological Institute and Hospital and Concordia University's PERFORM Center. The study objectives were to explore the potential beneficial effects of PoNS™ stimulation, as previously reported, and to provide data to be used for the design of future studies to support requests for marketing authorization.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements that have been prepared in accordance with U.S. GAAP. This preparation requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. U.S. GAAP provides the framework from which to make these estimates, assumption and disclosures. We choose accounting policies within U.S. GAAP that management believes are appropriate to accurately and fairly report our operating results and financial position in a consistent manner. Management regularly assesses these policies in light of current and forecasted economic conditions. Actual results could differ from those estimates made by management. While there are a number of significant accounting policies affecting our financial statements, we believe the critical accounting policies involving the most complex, difficult and subjective estimates and judgments are: valuation of non-monetary transactions, stock compensation for services, valuation of options and valuation of income taxes.

Stock-Based Compensation

We account for all of our stock-based payments and awards under the fair value based method. We recognize our stock-based compensation using the accelerated attribution method.

Stock-based payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting period of the award and in the same manner as if we had paid cash instead of paying with or using equity based instruments. The fair value of the stock-based payments to non-employees that is fully vested and non-forfeitable as at the grant date is measured and recognized at that date.

We account for the granting of share purchase options to employees using the fair value method whereby all awards to employees will be recorded at fair value on the date of the grant. The fair value of all share purchase options are expensed over their vesting period with a corresponding increase to additional capital surplus. Upon exercise of share purchase options, the consideration paid by the option holder, together with the amount previously recognized in additional paid-in capital is recorded as an increase to share capital. Share purchase options granted to employees are accounted for as liabilities when they contain conditions or other features that are indexed to other than a market, performance or service condition.

We use the Black-Scholes option pricing model to calculate the fair value of our share purchase options. Option pricing models require the input of highly subjective assumptions, including the expected price volatility. Changes in these assumptions can materially affect the fair value estimate.

Derivative Liabilities

We evaluate our financial instruments and other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market at each balance sheet date and recorded as a liability and the change in fair value is recorded in the consolidated statements of loss. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.

The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the balance sheet date.

We use the Black-Scholes option valuation model to value derivative liabilities. This model uses Level 3 inputs in the fair value hierarchy established by ASC 820 Fair Value Measurement

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Financial Instruments and Other Risks

We are exposed to credit risks and market risks related to changes to interest rates and foreign currency exchange rates, each of which could affect the value of our current assets and liabilities. We invest our cash equivalents in fixed rate, highly liquid and highly rated financial instruments such as guaranteed investment contracts, or GICs. At September 30, 2015, our cash and cash equivalents were held as cash. We do not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates relative to our investment portfolio, due to the relative short-term nature of the investments. We have not entered into any forward currency contracts or other financial derivatives to hedge foreign exchange risk. We are subject to foreign exchange rate fluctuations that could have a material effect on our total net assets or net loss. We are exposed to interest rate cash flow risk on our cash and cash equivalents as these instruments bear interest on current market rates

Item 4. Controls And Procedures

In connection with this quarterly report on Form 10-Q, under the direction of our Chief Executive Officer and our Chief Financial Officer, our management has evaluated our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act, and has concluded that our disclosure controls and procedures were ineffective as of September 30, 2015. As of the date of this filing, we are still in the process of remediating the material weakness that caused our disclosure controls and procedures to not be effective.

Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information we are required to disclose in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. In connection with the preparation of the consolidated financial statements for the year ended March 31, 2015, our management determined that our accounting staff does not have sufficient technical accounting knowledge relating to accounting for income taxes and complex U.S. GAAP matters, which our management determined has caused our disclosure controls and procedures to be ineffective.

We intend to take appropriate and reasonable steps to make the necessary improvements to our accounting staff to remediate this material weakness in our disclosure controls and procedures as resources to do so become available. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objective.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

On January 27, 2015 we received a demand letter containing allegations that we had entered into a consulting arrangement with the complainants and breached certain of its terms, and used certain intellectual property in the form of business and marketing plans allegedly prepared by the complainants, and seeking damages. On May 7, 2015, Mr. Rainier Maas and Dr. Jochen Scheld filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania seeking monetary damages in excess of \$225,000. We intend to conduct a vigorous defense of this matter. At this point management is unable to determine the outcome of this matter. Document discovery ends on October 23, 2015, a settlement conference with the magistrate judge is scheduled for December 2, 2015, discovery ends on February 26, 2016, and trial is scheduled for April 8, 2016. Management estimates that the contingent liability of such claim to be immaterial.

Except as described above, we are not aware of any legal proceedings contemplated by any governmental authority or any other party involving us or our properties. As of November 13, 2015, no director, officer or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has an adverse interest to us in any legal proceedings. We are not aware of any other legal proceedings pending or that have been threatened against us or our properties.

Item 1A. Risk Factors

There have been no material changes to the risk factors previously disclosed in our annual report on Form 10-K for the year ended March 31, 2015. You should carefully consider the risk factors discussed in Part I, “Item 1A. Risk Factors” in our annual report on Form 10-K for the year ended March 31, 2015, which could materially affect our business, financial condition and/or operating results. The risks described in our annual report on Form 10-K are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition and/or operating results.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

RECENT SALES OF UNREGISTERED SECURITIES

On June 26, 2015, the Company closed a private placement to seven accredited investors, which included one institution and six individuals, consisting of an aggregate of 335,463 units at a price of \$2.15 per unit for gross proceeds of \$721,243. Each unit issued in the private placements consisted of one share of the Company's common stock and one-half of one common share purchase warrant. Each whole warrant entitles the holder to purchase one additional share of the Company's common stock at a purchase price of \$3.00 for a period of thirty-six months.

On July 17, 2015, Helius Medical Technologies, Inc. (the "Company") closed a private placement to four accredited investors, which included three institutions and one individual, consisting of an aggregate of 125,756 units at a price of \$2.15 per unit for gross proceeds of approximately \$270,375. Each unit issued in the private placements consisted of one share of the Company's common stock and one-half of one common share purchase warrant. Each whole warrant entitles the holder to purchase one additional share of the Company's common stock at a purchase price of \$3.00 for a period of thirty-six months.

The Company relied on the exemption from registration provided by Section 4(a)(2) of the Securities Act and Rule 506(b) thereunder for the private placements. In connection with the July 17, 2015 and June 26, 2015 private placements, the Company issued 18,978 and 7,545 warrants, respectively, to an institutional accredited investor that served as finder for the private placements. The finder's warrants permit the holder to purchase one share of our common stock at a price of \$2.15 per share for a period of thirty-six months. We relied on the exemption from registration provided by Section 4(a)(2) of the Securities Act for the issuance of the finder's warrants.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
2.1	Agreement and Plan of Merger among Helius Medical Technologies, Inc., HMT Mergersub, Inc. and NeuroHabilitation Corporation, dated June 6, 2014 (incorporated by reference to Exhibit 10.6 to the Form S-1 filed with the Securities and Exchange Commission on July 14, 2014)
3.1	Articles of Continuation (incorporated by reference to Exhibit 3.1 to the Form S-1 filed with the Securities and Exchange Commission on July 14, 2014)
3.2	Articles of Amendment filed with the Wyoming Secretary of State on July 3, 2014 (incorporated by reference to Exhibit 3.2 to the Form S-1 filed with the Securities and Exchange Commission on July 14, 2014)

3.3	Articles of Amendment filed with the Wyoming Secretary of State on April 27, 2015 (incorporated by reference to Exhibit 3.3 to amendment no. 1 to the Form 10 filed on May 4, 2015)
3.4	Bylaws (incorporated by reference to Exhibit 3.3 to the Form S-1 filed with the Securities and Exchange Commission on July 14, 2014)
3.5	First Amendment to the Bylaws (incorporated by reference to Exhibit 3.4 to the Amendment to Form S-1 filed with the Securities and Exchange Commission on September 23, 2014)
3.6	Second Amendment to the Bylaws (incorporated by reference to Exhibit 3.3 to amendment no. 1 to the Form 10 filed on May 4, 2015)
31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 *
101.INS	XBRL Instance Document *
101.SCH	XBRL Taxonomy Extension Schema Document *
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document *
101.LAB	XBRL Taxonomy Extension Label Linkbase Document *
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document *
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document *

* filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

HELIUS MEDICAL TECHNOLOGIES, INC.

Date: November 16, 2015

By /s/ Philippe Deschamps
Philippe Deschamps
President and Chief Executive Officer

Date: November 16, 2015

By /s/ Joyce LaViscount
Joyce LaViscount
Chief Financial Officer (Principal Accounting Officer)

**Certification of Chief Executive Officer
of Period Report Pursuant to Rule 13a-14(a) and Rule 15d-14(a)**

I, Philippe Deschamps, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Heliuss Medical Technologies, Inc.;
 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
-

Date: November 16, 2015

/s/ Philippe Deschamps

Philippe Deschamps

President and Chief Executive Officer

**Certification of Chief Financial Officer
of Periodic Report Pursuant to Rule 13a-14(a) and Rule 15d-14(a)**

I, Joyce LaViscount, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Helius Medical Technologies, Inc.;
 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
-

Date: November 16, 2015

/s/ Joyce LaViscount

Joyce LaViscount

Chief Financial Officer

**Certification of Chief Executive Officer and Chief Financial Officer
Pursuant to
18 U.S.C Section 1350**

In connection with the quarterly report on Form 10-Q of Helius Medical Technologies, Inc. (the "Company") for the quarter ended September 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Philippe Deschamps, as Chief Executive Officer of the Company, and Joyce LaViscount, as Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his and her knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 16, 2015

/s/ Philippe Deschamps

Philippe Deschamps

President and Chief Executive Officer

/s/ Joyce LaViscount

Joyce LaViscount

Chief Financial Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Helius Medical Technologies, Inc. and will be retained by Helius Medical Technologies, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
